Therapeutics , Targets , and Chemical Biology KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells define commitment to apoptosis

  2013cited by this paper
• What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?

  2012cited by this paper
• Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

  2012cited by this paper
• Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.

  2012cited by this paper
• Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.

  2011cited by this paper
• Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.

  2011cited by this paper
• Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

  2011influential reference
• TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

  2010cited by this paper
• Extended kinase profile and properties of the protein kinase inhibitor nilotinib.

  2010cited by this paper
• Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib.

  2010cited by this paper
• Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.

  2009cited by this paper
• The stem cell factor–c-KIT pathway must be inhibited to enable apoptosis induced by BCR–ABL inhibitors in chronic myelogenous leukemia cells

  2009cited by this paper
• Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy.

  2008influential reference
• Fibroblast Growth Factor Receptor and Platelet-Derived Growth Factor Receptor Abnormalities in Eosinophilic Myeloproliferative Disorders

  2008influential reference
• BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.

  2008influential reference
• Human-hemato-lymphoid-system mice: opportunities and challenges.

  2007cited by this paper
• Crystal Structure of the T315I Mutant of Abl Kinase

  2007influential reference
• Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.

  2007cited by this paper
• In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.

  2006cited by this paper
• Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

  2006cited by this paper
• An efficient rapid system for profiling the cellular activities of molecular libraries.

  2006cited by this paper
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

  2006cited by this paper
• Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.

  2005cited by this paper
• Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.

  2004influential reference
• The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

  2004cited by this paper
• Oncogenes and Tumor Suppressors (795 articles)

  2004cited by this paper
• High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.

  2004cited by this paper
• Signal transduction via the stem cell factor receptor/c-Kit

  2004cited by this paper
• Control of Erythropoiesis by Erythropoietin and Stem Cell Factor: A Novel Role for Bruton’s Tyrosine Kinase

  2004influential reference
• Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase

  2004cited by this paper
• Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages.

  2004cited by this paper
• Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between Kit ligand and cytokines in primary primitive progenitor cells.

  2003influential reference
• Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent phosphorylation site mediating interaction with c-Crk.

  2003cited by this paper
• BCR–ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor

  2002cited by this paper
• Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells.

  1998influential reference
• The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.

  1997cited by this paper
• Lyn Associates with the Juxtamembrane Region of c-Kit and Is Activated by Stem Cell Factor in Hematopoietic Cell Lines and Normal Progenitor Cells*

  1997cited by this paper
• Assay systems for hematopoietic stem and progenitor cells

  1997cited by this paper
• Interaction of the receptor tyrosine kinase p145c‐kit with the p210bcr/abl kinase in myeloid cells

  1996cited by this paper
• Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia.

  1996influential reference
• Clinical Trials and Observations

  1996cited by this paper
• Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors.

  1995cited by this paper
• Transforming growth factor-beta prevents stem cell factor-mediated rescue of mast cells from apoptosis after IL-3 deprivation.

  1994cited by this paper

• No citing papers are available for this paper.